Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 Mpro
Vishal M. Balaramnavar*a,
Khurshid Ahmadb,
Mohd Saeedc,
Irfan Ahmadde,
Mehnaz Kamalf and
Talha Jawaidg
aDepartment of Medicinal and Pharmaceutical Chemistry, Global Institute of Pharmaceutical Education and Research, Jaspur Road, Kashipur, 244713, India. E-mail: v.balaramnavar@gmail.com
bDepartment of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, South Korea
cDepartment of Biology College of Sciences, University of Hail, Saudi Arabia
dDepartment of Clinical Laboratory Science, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia
eResearch Center for Advanced Materials Science, King Khalid University, Abha, Saudi Arabia
fDepartment of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, P.O. Box No. 173, Al-Kharj 11942, Kingdom of Saudi Arabia
gDepartment of Pharmacology, College of Medicine, Al Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317, Saudi Arabia
First published on 25th November 2020
Abstract
Correction for ‘Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 Mpro’ by Vishal M. Balaramnavar et al., RSC Adv., 2020, 10, 40264–40275, DOI: 10.1039/D0RA06038K.
The authors regret that the name of one of the authors (Talha Jawaid) was shown incorrectly in the original article. The corrected author list is as shown above.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2020 |